摘要
目的探索系统性红斑狼疮(systemic lupus erythematosus,SLE)患者皮肤损伤和狼疮性肾炎(lupus nephritis,LN)的蛋白质生物标志物,为SLE的诊断和控制提供依据。方法采用高通量蛋白质芯片技术检测SLE患者血清蛋白质生物标志物,针对皮肤损伤和LN这2种并发症对生物标志物进行单独和联合分析,寻找最佳诊断指标。结果单个指标转录因子5(transcription factor 5,SP5)、核糖体蛋白L7a(ribosomal protein L7a,RPL7A)以及联合指标[RPL7A+小核糖核蛋白多肽C(small nuclear ribonucleoprotein polypeptide C,SNRPC)]在皮肤损伤组及其对照组中具有最高的诊断价值。LN组与非LN组相比,SP5和[SP5+核糖体蛋白L35(ribosomal protein L35,RPL35)]的诊断价值最高。结论SP5可作为SLE患者皮肤损伤和LN诊断的蛋白质生物标志物。
Objective To explore protein biomarkers of skin lesions and lupus nephritis(LN)in patients with systemic lupus erythematosus(SLE),so as to provide evidence for diagnosis and control of the SLE.Methods High-throughput protein chip technology was used to identify serum protein biomarkers for SLE,and the biomarkers were analyzed individually and jointly for the two complications of skin lesions and LN to find the best diagnostic indicators.Results The separate indicators transcription factor 5(SP5),ribosomal protein L7 a(RPL7 A)and combined panel of(RPL7 A+small nuclear ribonucleoprotein polypeptide C(SNRPC))had the highest diagnostic value between skin lesions group and its control group.Compared with non-LN group,SP5 and(SP5+ribosomal protein L35(RPL35))had the highest diagnostic value in LN group.Conclusion SP5 can be used as a protein biomarker for diagnosis of skin lesions and LN in SLE patients.
作者
夏元睿
范引光
方心宇
叶冬青
XIA Yuan-rui;FAN Yin-guang;FANG Xin-yu;YE Dong-qing(Department of Epidemiology and Biostatistics,School of Public Health,Anhui Medical University,Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Hefei 230032,China)
出处
《中华疾病控制杂志》
CSCD
北大核心
2021年第8期928-934,共7页
Chinese Journal of Disease Control & Prevention
基金
国家自然科学基金(82073652,81872693,81673258)。